TWTaixiang Wu

Taixiang Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Taixiang Wu has a total of 185 co-authors. Here are the top co-authors by number of shared publications:

  • Jiafu Wei

    West China Hospital, Sichuan University; Department of Clinical Epidemiology; No. 37, Guo Xue Xiang Chengdu Sichuan China 610041

    9 shared publications
  • Juan Ni

    West China Hospital, Sichuan University; Department of Clinical Epidemiology; No. 37, Guo Xue Xiang Chengdu Sichuan China 610041

    8 shared publications
  • Likun Zhou

    West China Hospital, Sichuan University; Department of Clinical Epidemiology; No. 37, Guo Xue Xiang Chengdu Sichuan China 610041

    8 shared publications
  • Xiao Y Chen

    The General Hospital of the People's Liberation Army (PLAGH) (also Hospital 301); Department of Neurology; No. 28, Fuxing Road Beijing Beijing China 100853

    8 shared publications
  • Xiaoxi Zeng

    West China Hospital, Sichuan University; Department of Nephrology; 37 Guo Xue Xiang Chengdu Sichuan China 610041

    8 shared publications
  • Xunzhe Yang

    West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan, China, 610041

    8 shared publications

Latest Publications

  • Open Access

    Assessment of the reporting quality of randomised controlled trials of massage

    by Xuan Zhang, Lin Zhang, Weifeng Xiong, Xihong Wang, Xiaohan Zhou, Chen Zhao, Guihua Tian, Hongcai Shang, Taixiang Wu, Jiangxia Miao, et al.

    Objective: To assess the reporting quality of randomised controlled trials (RCTs) of massage, particularly whether necessary elements related to massage interventions were adequately reported.Methods: A total of 8 electronic databases were systematically searched for massage RCTs published in English and Chinese from the date of their inception to June 22, 2020. Quality assessment was performed using three instruments, namely the CONSORT (Consolidated Standards of Reporting Trials) 2010 Checklist (37 items), the CONSORT Extension for NPT (Nonpharmacologic Treatments) 2017 checklist (18 items), and a self-designed massage-specific checklist (16 items) which included massage rationale, intervention and control group details. Descriptive statistics were additionally used to analyse the baseline characteristics of included trials.Results: A total of 2,447 massage RCTs were identified, of which most (96.8%) were distributed in China. For the completeness of CONSORT, NPT Extension, and massage-specific checklists, the average reporting percentages were 50%, 10% and 45%, respectively. Of 68 assessed items in total (exclusion of 3 repeated items on intervention), 42 were poorly presented, including 18 CONSORT items, 15 NPT items, and 9 massage-specific items. Although the overall quality of reporting showed slightly improvement in articles published after 2010, the international (English) journals presented a higher score of the CONSORT and NPT items, while the Chinese journals were associated with the increased score of massage-specific items.Conclusion: The quality of reporting of published massage RCTs is variable and in need of improvement. Reporting guideline “CONSORT extension for massage” should be developed.


  • Open Access

    PRISMA extension for moxibustion 2020: recommendations, explanation, and elaboration

    by Xuan Zhang, Ran Tan, Wai Ching Lam, Chung Wah Cheng, Liang Yao, Xiao-Qin Wang, Si-Yao Li, Qi-Ying Aixinjueluo, Ke-Hu Yang, Hong-Cai Shang, et al.

    Background: Moxibustion is a common intervention of Chinese medicine (CM). Systematic reviews (SRs) on moxibustion are increasing. Although the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement provides guidelines for SRs, the quality of moxibustion-related SRs is still not satisfactory. In particular, descriptions of the interventions and the rationale for using moxibustion are insufficient. To address these inadequacies, the working group developed this PRISMA extension for reporting SRs of moxibustion (PRISMA-M 2020). Methods: A group of CM clinical professionals, methodologists of SRs, reporting guideline developers, and journal editors developed this PRISMA-M 2020 through a comprehensive process that includes registration, literature review, consensus meetings, Delphi exercises for soliciting comments, and revision, resulting in this final draft. Results: Seven of the 27 PRISMA checklist items, namely title (1), rationale (3), eligibility criteria (6), data item (11), additional analyses (16), study characteristics (18), and additional analysis (23), were extended, with specific reference to the application of moxibustion. Illustrative examples and explanations for each item are provided. Conclusion: The PRISMA-M 2020 will help improve the reporting quality of SRs with moxibustion. Systematic review registration: We have registered it on the EQUATOR (Enhancing the QUAlity and Transparency Of health Research) network, particularly under the item of PRISMA-TCM: http://www.equator-network.org/library/reporting-guidelines-under-development/reporting-guidelines-under-development-for-systematic-reviews/#65.


  • Open Access

    Standards for reporting interventions in clinical trials of cupping (STRICTOC): extending the CONSORT statement

    by Xuan Zhang, Ran Tian, Wai Ching Lam, Yuting Duan, Fan Liu, Chen Zhao, Taixiang Wu, Hongcai Shang, Xudong Tang, Aiping Lyu, et al.

    Background: The standards for reporting interventions in clinical trials of cupping (STRICTOC), in the form of a checklist and explanations for users, were designed to improve reporting of cupping trials, particularly the interventions, and thereby facilitating their interpretation and replication. Methods: A group of clinical experts, methodologists, epidemiologists, and editors has developed this STRICTOC checklist through a comprehensive process, including registration of this guideline, literature review, solicitation of comments, consensus meeting, revision, and finalization. Results: The STRICTOC checklist includes 6 items and 16 sub-items, namely cupping rationale, details of cupping, treatment regimen, other components of treatment, treatment provider background, and control or comparator interventions. Illustrative examples of each item are also provided. Conclusions: It is intended that the STRICTOC, in conjunction with both the main Consolidated Standards of Reporting Trials (CONSORT) Statement and extension for nonpharmacologic treatment, will raise the reporting quality of clinical trials of cupping. Trial registration We have registered this study on the Enhancing the Quality and Transparency of Health Research (EQUATOR) Network: http://www.equator-network.org/library/reporting-guidelines-under-development/reporting-guidelines-under-development-for-clinical-trials/#STRICTOC.


  • Top Cited Papers
    Open Access

    Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist

    by Xiaoqin Wang, Yaolong Chen, Yali Liu, Liang Yao, Janne Estill, Zhaoxiang Bian, Taixiang Wu, Hongcai Shang, Myeong Soo Lee, Dang Wei, et al.

    Acupuncture is widely used worldwide, and systematic reviews on acupuncture are increasingly being published. Although acupuncture systematic reviews share several essential elements with other systematic reviews, some essential information for the application of acupuncture is not covered by the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement. Considering this, we aimed to develop an extension of the PRISMA statement for acupuncture systematic reviews. We used the PRISMA statement as a starting point, and conducted this study referring to the development strategy recommended by the EQUATOR network. The initial items were collected through a wide survey among evidence users and a review of relevant studies. We conducted a three-round Delphi survey and one-day face-to-face meeting to select items and formulate the checklist. After the consensus meeting, we drafted the manuscript (including the checklist) and sent it to our advisory experts for comments, following which the checklist was refined and circulated to a group of acupuncture systematic review authors for pilot test. We also selected a sample of acupuncture systematic reviews published in 2017 to test the checklist. A checklist of five new sub-items (including sub items) and six modified items was formulated, involving content related to title, rationale, eligibility criteria, literature search, data extraction, and study characteristics. We clarified the rationales of the items and provided examples for each item for additional guidance. The PRISMA for Acupuncture checklist is developed for improving the reporting of systematic reviews of acupuncture interventions. We have registered the study on the EQUATOR network ( http://www.equator-network.org/library/reporting-guidelines-under-development/#91 ).


  • Open Access

    Beta-blockers for unstable angina

    by Taixiang Wu, Xiyang Chen, Lei Deng

  • Prostaglandin E1 for diabetic neuropathy

    by Ya Li, Haoming Tian, Taixiang Wu

  • Open Access

    Chemotherapy with Camptothecin compounds for metastatic colorectal cancer

    by Donghao Lu, Huan Song, Fan He, Beibei Cui, Yalun Li, Taixiang Wu

  • Retraction
    Open Access

    Chuanxiong preparations for preventing stroke

    by Xunzhe Yang, Xiaoxi Zeng, Taixiang Wu


  • Retraction

    Puerarin injection for unstable angina pectoris

    by Qin Wang, Taixiang Wu, Xiao Y Chen, Xin Duan, Jie Zheng, Jieqi Qiao, Likun Zhou, Jiafu Wei, Juan Ni

    Puerarin is extracted from the Chinese herb puerariae lobata. Many users of Chinese herbal medicine believe that puerarin has positive effects in the treatment of coronary heart disease (CHD). In recent years puerarin injection has been widely used to treat CHD and angina pectoris.To assess the benefits and harms of puerarin injection for unstable angina.The following electronic databases were searched: The Cochrane Controlled Trials Register on The Cochrane Library (Issue 3, 2004), MEDLINE (1995 to 2004), EMBASE (1995 to 2004), CBM (1995 to 2004), Chinese Cochrane Centre Controlled Trials Register (to 2004), Current Controlled Trials (www.controlled-trials.com) and The National Research Register. We also hand searched 60 Chinese traditional medicine journals.Randomised controlled trials undertaken on adults with unstable angina evaluating the following types of interventions: Puerarin injection compared to western drugs or placebo, or puerarin injection used with western drugs compared to western drugs alone.Data were extracted and analysed independently by two reviewers. Differences in data extraction and analysis were resolved by consensus, referring back to the original article. Study authors were contacted for additional information. Adverse effects information was collected from the trials.20 trials involving 1240 people were included. All trials identified were classified as having a high risk of bias because of poor reported methodology. The duration of treatment was 7-20 days and no information supplied suggested longer follow-ups were conducted for any trials. This limited the observation to participants who were not undertaking normal activities of daily living.The primary outcome (death) was not report in any trial. For all the secondary outcome measures, frequency of acute angina attacks, improvements in ECG, doses and incidence of nitroglycerine needed and levels of plasma endothelin, there was no evidence that puerarin had better or worse effects to other conventional treatments. There was strong evidence to suggest that puerarin injection plus western drugs was a better treatment option than western drugs alone.Puerarin injection may be effective in unstable angina when used in addition to conventional treatments. However, these finding should be interpreted with care because of the very low methodological quality of studies and potential publication bias. In the light of the findings, a more rigorously designed, randomised double-blind placebo-controlled trial is needed.